(Q46174958)

English

Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study

scientific article published on 22 May 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23706985

Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study (English)

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23706985

0 references

1 reference

based on heuristic

inferred from title

author name string

Yoo-Joung Ko

1

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23706985

Christine M Canil

2

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23706985

Som D Mukherjee

3

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23706985

Eric Winquist

4

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23706985

Christine Elser

5

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23706985

Andrea Eisen

6

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23706985

M Neil Reaume

7

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23706985

Liying Zhang

8

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23706985

Srikala S Sridhar

9

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23706985

publication date

22 May 2013

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23706985

Lancet Oncology Commission

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23706985

14

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23706985

769-776

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23706985

8

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23706985

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A Phase II study of oxaliplatin in urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Isolation and characterization of a cell surface albumin-binding protein from vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: preliminary findings

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970162-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(13)70162-1

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23706985

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23706985

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46174958&oldid=2097451782"